Could a cheap antiseptic wash cut surgery infections?
NCT ID NCT06869096
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares rinsing the surgical area with chlorhexidine (an antiseptic) versus saline (salt water) during colorectal cancer surgery. The goal is to see if chlorhexidine reduces surgical site infections and other complications within 30 days. About 532 adults with resectable colorectal tumors are being enrolled.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- chlorhexidine solution
- What this could lead to
- If it works, this could point toward a simple, low-cost way to lower infection risk after colorectal cancer surgery.
- What could go wrong
- This is a mid-sized trial, but it is not a cure—it tests a routine procedure. The benefit may be small or not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 532 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2024
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients aged 18-85 years, 2. Patients with surgically resectable colorectal tumors confirmed by CT/MRI before surgery 3. All patients had a performance status score of 0 or 1 in the Eastern Tumor Cooperative group 4. American Society of Anesthesiology grade I-III Exclusion Criteria: 1. The tumor may have distant metastasis 2. History of previous abdominal surgery 3. The patient has a history of other malignant tumors diagnosed in the past 5 years and has received radiotherapy and chemotherapy in the past 4. There are obvious contraindications to surgery (obvious abnormal liver and kidney function, pregnancy) 5. Participated in other clinical trials within the past 6 months
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chlorhexidine are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Nanchong Central Hospital
RECRUITINGNanchong, Sichuan, 637000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gut bacteria may hold clues to why some cancer treatments work better
- Burning the edges: a new way to stop colon polyps from coming back
- Missed Follow-Up colonoscopies: do they raise the risk of advanced growths?
- A 2.2 mm scope could spot cancerous tissue in minutes, not days
- Can plain water replace a common ICU mouthwash?
- The gatekeepers of tumors: scientists probe how blood vessels let immune cells in